Summary
Profile
Financials
Events
Ownership
Options

Company Info

Industry Biotechnology
Sector Health Technology
Employees 432
CEO Mr. Richard A. Paulson
Address 85 Wells Avenue 2nd floor, Newton, MA 02459
Phone 1.617.658.0600
Website www.karyopharm.com

Karyopharm Therapeutics, Inc. is a commercial-stage pharmaceutical company pioneering novel cancer therapies and dedicated to the discovery, development, and commercialization of first-in-class drugs directed against nuclear export for the treatment of cancer and other diseases. Its Selective Inhibitor of Nuclear Export (SINE) compounds function by binding with and inhibiting the nuclear export protein XPO1 (or CRM1). Karyopharm’s compound, XPOVIO (selinexor), is approved in the U.S. in multiple hematologic malignancy indications, including in combination with Velcade (bortezomib) and dexamethasone for the treatment of adult patients with multiple myeloma after at least one prior therapy, in combination with dexamethasone for the treatment of adult patients with pretreated multiple myeloma and as a monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma. In addition to single-agent and combination activity against a variety of human cancers, SINE compounds have also shown biological activity in models of neurodegeneration, inflammation, autoimmune disease, certain viruses, and wound-healing. Karyopharm has several investigational programs in clinical or preclinical development. The company was founded by Joseph Araujo, Ronald A. DePinho, Pamela A Silver, Giulio Draetta, Michael G. Kauffman, and Sharon Shacham on December 22, 2008 and is headquartered in Newton, MA.

Competitors

Company Name 3 Month
%Change
1 Year
%Change
Karyopharm Therapeutics, Inc. -39.17% -64.37%
Rani Therapeutics Holdings, Inc. n/a n/a
Scholar Rock Holding Corp. -6.64% 95.06%
Endo International Plc 19.48% -16.77%
Kinnate Biopharma, Inc. 10.06% n/a

Statement Summary

as of 4:00 ET PM 10/14/2021
Total Assets (MRQ) 286.6 M
Total Liabilities (MRQ) 369.7 M
Shareholders’ Equity (MRQ) -83.1 M
Total Revenue (Annual) 22.6 M
Net Income (Annual) -53.6 M

Earnings And Estimates

as of 4:00 ET PM 10/14/2021

Current Qtr EPS Estimate -0.67
Current FY EPS Estimate -2.84
Long Term EPS Growth Estimate -49.42
Next Expected Earnings Date 11/8/2021

KPTI vs S&P 500

as of 10/14/2021
Relative To
S&P 500
KPTI
4 Weeks n/a n/a
12 Weeks n/a n/a
YTD n/a n/a

Earnings Surprises

as of 4:00 ET PM 10/14/2021
Fiscal Quarter Estimate Actual Surprise
06/2021 -0.75 -0.71 -4.70%
03/2021 -0.71 -0.77 +8.62%
12/2020 -0.59 -0.59 -0.34%
09/2020 -0.70 -0.73 +3.84%
06/2020 -0.58 -0.63 +8.43%
03/2020 -0.69 -0.78 +12.43%
12/2019 -0.67 -0.76 +13.43%
09/2019 -0.83 -0.67 -18.91%

Financial Strength

as of 4:00 ET PM 10/14/2021
Pre-Tax Margin -236.49
Net Margin -71.14
Operating Margin -217.02
Return On Equity -891.05
Return On Assets -62.38
Inventory Turnover (TTM) 1.63
Sales Growth (MRQ) 236.64

Ratios

as of 4:00 PM ET 10/14/2021
Price/Earnings (TTM) n/a
Price/Book (MRQ) 0.00
Price/Cash Flow (TTM) 0.00
Book Value (MRQ) -1.10
Quick Ratio (MRQ) 4.64
Current Ratio (MRQ) 4.71
Total Debt/Equity (MRQ) 0.00

Short Interest

as of 4:00 PM ET 10/15/2021
% Short - 0.00%
% Remaining Float - 100.00%
Current Last Month
Short Interest Date n/a n/a
Short Interest Shares 0 0
Short Interest Ratio 0.0 0.0
M Y M Y
Total Assets 0,0.00 0,0.00
Total Liabilities 0,0.00 0,0.00
Total Equity 0,0.00 0,0.00
M Y M Y
Total Revenue 0,0.00 0,0.00
EBT Exc.
Unusual Items
0,0.00 0,0.00
Net Income 0,0.00 0,0.00
M Y M Y
Cash from
Operations
0,0.00 0,0.00
Cash from
Activities
0,0.00 0,0.00
Cash from
Fin. Activities
0,0.00 0,0.00

TOTAL ASSETS

TOTAL LIABILITIES

TOTAL EQUITY

Balance Sheet

M Y
ASSETS
Cash And Equivalents 0,0.00
Receivables 0,0.00
Inventories 0,0.00
Other Current Assets 0,0.00
Total Current Assets 0,0.00
Property, Plant & Equipment, Gross 0,0.00
Accumulated Depreciation & Depletion 0,0.00
Property, Plant & Equipment, Net 0,0.00
Intangibles 0,0.00
Other Non-Current Assets 0,0.00
Total Non-Current Assets 0,0.00
TOTAL ASSETS 0,0.00
Liabilities & Shareholder Equity
Accounts Payable 0,0.00
Short Term Debt 0,0.00
Total Current Liabilities 0,0.00
Long Term Debt 0,0.00
Deferred Income Taxes 0,0.00
Other Non-Current Liabilities 0,0.00
Minority Interest 0,0.00
Total Non-Current Liabilities 0,0.00
Preferred Stock Equity 0,0.00
Common Stock Equity 0,0.00
Common Par 0,0.00
Additional Paid In Capital 0,0.00
Cumulative Translation Adjustment 0,0.00
Retained Earnings 0,0.00
Treasury Stock 0,0.00
Other Equity Adjustments 0,0.00
Total Capitalization 0,0.00
TOTAL EQUITY 0,0.00
TOTAL LIABILITIES & STOCK EQUITY 0,0.00
Total Common Shares Outstanding 0,0.00
Preferred Shares 0,0.00
Treasury Shares 0,0.00
Basic Weighted Shares Outstanding 0,0.00
Diluted Weighted Shares Outstanding 0,0.00
Number Of Employees 0,0.00
Number Of Part-Time Employees 0,0.00

TOTAL REVENUES

EBT Excluding Unusual Items

NET INCOME

Income Statement

M Y
Sales 0,0.00
Cost Of Sales 0,0.00
Gross Operating Profit 0,0.00
Selling, General, And Administrative Expenses 0,0.00
Research & Development 0,0.00
Operating Income Before D & A (EBITDA) 0,0.00
Depreciation & Amortization 0,0.00
Interest Income 0,0.00
Other Income - Net 0,0.00
Special Income / Charges 0,0.00
Total Income Before Interest Expenses (EBIT) 0,0.00
Interest Expense 0,0.00
Pre-Tax Income 0,0.00
Income Taxes 0,0.00
Minority Interest 0,0.00
Net Income From Continuing Operations 0,0.00
Net Income From Discontinued Operations 0,0.00
Net Income From Total Operations 0,0.00
Extraordinary Income/Losses 0,0.00
Income From Cum. Effect Of Acct. Change 0,0.00
Income From Tax Loss Carryforward 0,0.00
Other Gains / Losses 0,0.00
Total Net Income 0,0.00
Normalized Income
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
0,0.00
Preferred Dividends 0,0.00
Net Income Available To Common 0,0.00
Basic EPS From Continuing Ops. 0,0.00
Basic EPS From Discontinued Ops. 0,0.00
Basic EPS From Total Operations 0,0.00
Basic EPS From Extraordinary Inc. 0,0.00
Basic EPS From Cum Effect Of Accounting Change 0,0.00
Basic EPS From Tax Loss Carryf'd. 0,0.00
Basic EPS From Other Gains (Losses) 0,0.00
Basic EPS, Total 0,0.00
Basic Normalized Net Income/Share 0,0.00
EPS From Continuing Ops. 0,0.00
EPS From Discontinued Ops 0,0.00
EPS From Total Ops. 0,0.00
EPS From Extraord. Inc. 0,0.00
EPS From Cum Effect of Accounting Change 0,0.00
EPS From Tax Loss Carfd. 0,0.00
EPS From Other Gains (L) 0,0.00
EPS, Total 0,0.00
Diluted Normalized Net Inc/Shr
(Net Income From Continuing Operations,
Ex. Special Income / Charge)
0,0.00
Dividends Paid Per Share 0,0.00

CASH FROM OPERATIONS

CASH FROM INVESTING ACTIVITIES

CASH FROM FINANCING ACTIVITIES

Cash Flow Statement

M Y
Cash Flow From Operating Activities
Net Income (Loss) 0,0.00
Operating Gains/Losses 0,0.00
Gross Operating Profit 0,0.00
(Increase) Decrease In Receivables 0,0.00
(Increase) Decrease In Inventories 0,0.00
(Increase) Decrease In Other Current Assets 0,0.00
(Decrease) Increase In Other Current Liabilities 0,0.00
(Increase) Decrease In Other Working Capital 0,0.00
Other Non-Cash Items 0,0.00
Net Cash From Continuing Operations 0,0.00
Net Cash From Discontinued Operations 0,0.00
Cash Provided By Investing Activities
Net Cash From Total Operating Activities 0,0.00
Sale Of Property, Plant & Equipment 0,0.00
Cash Used For Investing Activities
Sale Of Short-Term Investments 0,0.00
Purchases Of Property, Plant & Equipment 0,0.00
Acquisitions 0,0.00
Purchases Of Short-Term Investments 0,0.00
Other Cash From Investing Activities 0,0.00
Cash Provided by Financing Activities
Net Cash From Investing Activities 0,0.00
Issuance Of Debt 0,0.00
Cash Used For Financing Activities
Issuance Of Capital Stock 0,0.00
Repayment Of Long-Term Debt 0,0.00
Repurchase Of Capital Stock 0,0.00
Payment Of Cash Dividends 0,0.00
Other Financing Charges, Net 0,0.00
Net Cash From Financing Activities 0,0.00
Effect Of Exchange Rate Changes 0,0.00
Net Change In Cash & Cash Equivalents 0,0.00

Earnings Estimates

as of 4:00 ET PM 10/14/2021
Current Qtr
(09/2021)
Next Qtr
(12/2021)
Consensus Estimate $-0.67 $-0.69
# of Estimates 9 9
High Estimate $-0.56 $-0.53
Low Estimate $-0.73 $-0.79
Year Ago EPS $-0.73 $-0.59
Year Over Year Growth Estimate -7.53% 17.17%
Current Yr
(12/2021)
Next Yr
(12/2022)
Consensus Estimate $-2.84 $-2.06
# of Estimates 9 9
High Estimate $-2.50 $-1.34
Low Estimate $-3.00 $-2.77
Year Ago EPS $-2.72 $-2.84
Year Over Year Growth Estimate 4.25% -27.43%
Current Qtr
(09/2021)
Next Qtr
(12/2021)
Current Year
(12/2021)
Next Year
(12/2022)
Consensus Estimate $-0.67 $-0.69 $-2.84 $-2.06
# of Estimates 9 9 9 9
High Estimate $-0.56 $-0.53 $-2.50 $-1.34
Low Estimate $-0.73 $-0.79 $-3.00 $-2.77
Year Ago EPS $-0.73 $-0.59 $-2.72 $-2.84
Year Over Year Growth Estimate -7.53% 17.17% 4.25% -27.43%

Insider Information Summary

as of 09/30/2021
% Insiders - 12.95%
% Remaining Total Shares - 87.05%
Current 1 Month
Net Insider Transaction 6.84 K 13.31 K
Shares Bought 7.50 K 14.50 K
Shares Sold 665.00 1.19 K

Insider Activity

Transaction Date Insider/Title Transaction Type Market Value Shares Average Price Current Holdings

LATEST NEWS

Recent Articles from TheStreet

How Legion M Plans to Take Down the Hollywood Studios

Hollywood Film and TV Crews Union Agreement Averts Strike

Hollywood film and television production crews avert a nationwide strike after reaching a tentative agreement with movie and TV production companies.

Chinese Medical Device Maker Contec Rides Pandemic Demand To Score 12-fold Share Price Gain On Shenzhen Debut

Cramer: Sharecare’s Low Share Price Makes the Stock Worth a Look

Technical indicators for health tech company's shares appear to be improving.

united-airlines (2)

United Airlines COVID-19 Vaccine Mandate Prompts Judge's TRO

United Airlines temporarily can't force employees to take unpaid leave if they have a medical or religious excuse from taking the COVID-19 vaccine.

SPAC Lead

Digital Asset Firm Bakkt Completes SPAC Merger With VPC

Digital asset marketplace and wallet provider Bakkt closed its SPAC merger with VPC Impact Acquisition Holdings.

Nucor Lead

Cramer: Now Is Not the Time to Sell Nucor Steel Stock

Upside remains for steelmaker even after key downgrade, as infrastructure spending is still in play in Washington.

Levi Strauss Lead

Levi Strauss Bullish on Next-Gen Retail

The direct-to-consumer stores focus on local personalization, customization and digitalization.

Wall Street Lead

Cramer's Mad Money Recap: J&J, Netflix, Nvidia, Tesla

Cramer says the clouds over Wall Street may have broken. Get ready for next week's earnings parade.

Here Is What Jim Cramer Expects From Schlumberger's Earnings

Energy Stocks Emerge as Leaders: Curran

Years of underperformance appear over for hard-hit oil and gas stocks.

Dave Chappelle Netflix Lead

Netflix Employee Reportedly Laid Off Over Chappelle Show Leak

Internal unrest over content of comedian's latest program continues at streaming giant.

crypto copy

Stablecoin Issuer Tether Agrees to $41 Million Settlement with CTFC

Tether made 'untrue or misleading statements and omissions in connection with the U.S. dollar tether token stablecoin,' the CFTC said.